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Abstract
Microenvironment and activation signals likely imprint heterogeneity in the lymphatic endo-
thelial cell (LEC) population. Particularly LECs of secondary lymphoid organs are exposed
to different cell types and immune stimuli. However, our understanding of the nature of LEC
activation signals and their cell source within the secondary lymphoid organ in the steady
state remains incomplete. Here we show that integrin alpha 2b (ITGA2b), known to be car-
ried by platelets, megakaryocytes and hematopoietic progenitors, is expressed by a lymph
node subset of LECs, residing in medullary, cortical and subcapsular sinuses. In the sub-
capsular sinus, the floor but not the ceiling layer expresses the integrin, being excluded
from ACKR4+ LECs but overlapping with MAdCAM-1 expression. ITGA2b expression
increases in response to immunization, raising the possibility that heterogeneous ITGA2b
levels reflect variation in exposure to activation signals. We show that alterations of the
level of receptor activator of NF-κB ligand (RANKL), by overexpression, neutralization or
deletion from stromal marginal reticular cells, affected the proportion of ITGA2b+ LECs.
Lymph node LECs but not peripheral LECs express RANK. In addition, we found that lym-
photoxin-β receptor signaling likewise regulated the proportion of ITGA2b+ LECs. These
findings demonstrate that stromal reticular cells activate LECs via RANKL and support the
action of hematopoietic cell-derived lymphotoxin.
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Introduction
Molecules, cells and pathogens carried by the lymph flow are filtered by lymph nodes (LNs). In
these specialized organs, resident immune cells recognize, eliminate and mount an immune
response against pathogens. The LECs provide an important structural and functional support
to this process by mediating lymph drainage, organizing cellular compartments, regulating the
immune response and controlling lymph exit [1]. Lymph first drains into the subcapsular
sinus, which comprises an outermost (ceiling-lining) and an inner (floor-lining) lymphatic
endothelial layer. Differential expression of the chemokine ACKR4 (also called CCRL1) has
recently highlighted structural and functional specialization of these layers [2]. LECs also form
the cortical and medullary sinuses that allow distribution of cells and large molecules within
different LN compartments and exit into the efferent lymph [3]. Platelet adhesion to lymphatic
endothelium mediates blood and lymphatic vessel separation during embryonic development
[4].
Integrins play an important role in a variety of biological processes ranging from develop-
ment, cancer, and inflammation [5]. The large family of transmembrane receptors, composed
of α and β subunits, provides structural and functional integrity to connective tissues and
organs, mediates cell extravasation from blood and contributes to cell activation. The integrin
α2b (ITGA2b, CD41 or glycoprotein IIb) pairs exclusively with integrin β3 (ITGB3, CD61 or
glycoprotein IIIa), while the latter can also form a heterodimer with integrin αV (ITGAV,
CD51). ITGA2B/ITGB3 is well known for its role in blood clotting through its expression by
megakaryocytes and platelets [6]. Upon platelet stimulation, the surface integrin heterodimer
becomes activated, binds fibrinogen and vonWillebrand factor resulting in platelet aggrega-
tion. ITGA2b and ITGB3 are also expressed by embryonic erythroid and hematopoietic pro-
genitor cells arising from the hemogenic endothelium of the conceptus and embryo [7–9].
Although hemogenic endothelium generates ITGA2b+ hematopoietic progenitor cells, these
special endothelial cells themselves lack the integrin [7]. Otherwise, blood endothelial cells
express a number of integrins, both in the abluminal space to adhere to the basement mem-
brane and in the lumen to recruit leucocytes [5].
The TNF family member RANKL (TNFSF11), alike other member of the protein family
such as lymphotoxin-α and β, plays an important role in LN development [10]. It is expressed
in the embryo by the hematopoietic lymphoid tissue inducing cells and triggers lymphotoxin
production [11]. In a second phase RANKL is expressed by the lymphoid organizer cells of
mesenchymal origin [12], which are thought to persist as marginal reticular cells (MRCs) in
the adult [13]. The role of RANKL produced by MRCs remains unknown. In a model of skin
overexpression RANKL was shown to activate LN lymphatic and blood endothelial cells as well
as fibroblastic reticular cells raising the possibility that RANKL of MRCs functions as internal
activator of these cells [14].
In this study, we show that a subset of LECs of mouse and human LNs express ITGA2b. In
the murine LN the ITGA2b+ LECs are heterogeneously distributed in the medullary and corti-
cal areas as well as in the subcapsular sinus, where only the floor-lining cells carry the integrin.
ITGA2b could potentially heterodimerize with ITGB3 to bind ligands, such as fibronectin, but
the alternative α-chain, ITGAV, is also present to pair with ITGB3 to anchor the cells to matrix
components. In mice overexpressing RANKL the level of ITGA2b increases, while its neutrali-
zation or its genetic deletion from MRCs reduce the integrin expression. Similarly, inhibition
of lymphotoxin-β receptor signaling negatively affects the proportion of ITGA2b+ LECs.
Therefore, ITGA2b is a novel marker for LN LECs constitutively activated by TNF-family
members RANKL and lymphotoxin-αβ.
RANKL Activates Lymphatic Integrin-αIIb Expression
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Material and Methods
Mice
C57BL/6, Itga2b-/- [15], ACKR4-eGFP transgenic mice (otherwise known as CCRL-1-eGFP)
[2], RANK-transgenic [14], and RANKLΔCcl19mice were bred and kept in specific pathogen-
free conditions, and all experiments were carried out in conformity to the animal bioethics leg-
islation approved by and according to national guidelines of the CREMEAS (Comité Régional
d’Ethique en Matière d’Expérimentation Animale de Strasbourg), permit number AL/02/22/
11/11 and AL/03/12/05/12. All efforts were made to minimize suffering. To generate mice with
conditional RANKL deficiency in marginal reticular cells (RANKLΔCcl19), mice containing a
single copy of the Ccl19-cre BAC transgene [16] were crossed with RANKLf/f
(B6.129-Tnfsf11tm1.1Caob/J) mice [17]. For adoptive bone marrow transfer, 6-wk-old mice
were lethally irradiated with 9 Gy (Caesium source), and 3 h later they received 5x106 bone
marrow cells i.v. harvested from Itga2b-/- mice. Chimerism was complete by the absence of
ITGA2b on platelets.
Preparation of LN Stromal Cells
Stromal cells were prepared from murine peripheral (inguinal, axial and brachial) or mesen-
teric LNs as previously described [18]. CD45+ and TER119+ cells were depleted using anti-
TER119 and anti-CD45 coupled magnetic beads (Miltenyi Biotec). Use of all human tissues
was approved by the Medical Ethical Commission of the Erasmus University Medical Center
Rotterdam and was contingent on written informed consent from the donor. Stromal cells
from human LNs were obtained as described [19].
Flow Cytometry and Cell Sorting
All reactions were performed at 4°C for 20 min in PBS supplemented with 2% FCS and 2.5
mM EDTA. The following antibodies were used for flow cytometry: CD45-APC/CY7 (30-F11,
Biolegend), Ter119-APC/CY7 (Ter119, Biolegend), gp38/podoplanin-A488 (8.1.1, Biolegend),
CD31-PcPeF710 (390, eBioscience), ITGA2b (APC-conjugated MWReg30, Biolegend,
A647-conjugated RAM-2), ITGB3-PE (2C9.G2, Biolegend), glycoprotein subunit IBβ-A647
(RAM-1 [20]), ITGAV-PE (RMV-7, eBioscience), CD3-FITC (145-2C11, BD), CD19-APC
(1D3, BD), CD103-PerCP-Cy5.5 (M290, BD), CD11c-PerCP-Cy5.5 (N418, BD), RANK-02
[21] or their isotype controls. Integrin αIIbβ3-PE (JON/A, EMFRET analytics GmbH, Eibel-
stadt, Germany) was used to stain for the active integrin conformation in tyrode-albumin
buffer pH 7.3 (137 mMNaCl, 2,7mM KCl, 12mM NaHCO3, 0.36 mMNaH2PO4, 1mM
MgCl2, 2mM CaCl2, 5mM Hepes, 0,35% albumin, 5.55 mMGlucose). Flow cytometry was
performed on a Gallios (Beckman-Coulter, Fullerton, CA, USA) or a Fortessa X-20 SORP (BD)
and analyzed with FlowJo software (Treestar, Ashland, OR, USA). For flow cytometric analysis
of human fetal LNs the following antibodies were used: gp38/podoplanin A488 (NC-08, Biole-
gend), CD31 Pacific-blue (WM59, Biolegend), CD45 PE-Cy7 (HI30, Biolegend), and mouse
anti-Donkey A647 (Life technologies). Primary antibodies were added to the cells for 30 min at
4°C. Then, cells were stained with secondary antibodies for 20 min at 4°C.
Lymphatic Endothelial Cell Culture
LECs were cell-sorted based on gp38 and CD31 expression and cultured in a single drop of
endothelial cell growth medium (Lonza) in culture slides (Corning) pre-coated with 5 μg/cm2
of fibronectin and collagen (Sigma-Aldrich) over-night at 37°C 5% CO2. The next day, 300 μl
of endothelial cell growth medium were added. Cells were fixed in 4% formaldehyde and then
RANKL Activates Lymphatic Integrin-αIIb Expression
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stained for ITGA2b and mCLCA1 with DAPI nuclear counterstain. Images were acquired on a
Microscope Zeiss Axio Observer Z1 Confocal LSM780 (Carl Zeiss) with the Carl Zeiss proprie-
tary software Zen and on a spinning disk inverted microscope (Carl Zeiss) with a confocal
head Yokogawa CSU and a Metamorph software (Metamorph). Analysis of all microscopic
images was done using the open source imageJ-based Fiji distribution.
Immunofluorescence
Organs were embedded in Tissue-Tek O.C.T Compound (Electron Microscopy Science) and
frozen in liquid nitrogen. Six to 8 μm sections were cut, fixed in cold acetone and then blocked
with 2% BSA. The following antibodies were used: mCLCA1 (hamster mAb 10.1.1), Lyve-
1-A488 (ALY7, eBioscience), ITGA2b-APC (MWReg30, Biolegend), Prox-1 (polyclonal goat,
R&D Systems), GPIbß (RAM1-A645), MAdCAM-1 (MECA-367, BD-Pharmingen), fibronec-
tin (Rabbit polyclonal, Patricia Simon-Assmann, UMR-S 1109 INSERM, Strasbourg), RANKL
(IK22.5, Rat IgG2a, [22]), goat anti-rabbit-A488 (Molecular Probes), goat anti-hamster-A488/
A546 (Molecular Probes), donkey anti-rat-Cy3 (Jackson) or streptavidin A546 or A647
(Molecular Probes). Sections were mounted using DAKOmounting medium (Dako, Hamburg,
Germany). Images were acquired and treated as noted above.
Transmission Electron Microscopy
ITGA2b+ sorted LECs were fixed in 2.5% glutaraldehyde for 1 h and 200 μl blue AccuDropsR
beads (BD Biosciences) were added to facilitate cell pellet visualization during the subsequence
sample preparation as described [23]. Cells were visualized on a CM120 microscope with biot-
win lens configuration operating at 120 kV (FEI, Eindhoven, The Netherlands)
Quantitative Reverse Transcription Coupled Polymerase Chain
Reaction (qRT-PCR)
RNA from total LNs and from sorted LECs were extracted with RNeasy kits (Qiagen) and
cDNA was synthesized with Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) and
Improm-II (Promega) using oligo(dT)15 primers. RT-PCR was performed using Luminaris
color HiGreen qPCR Master Mix (Thermo Scientific) using the following primers to amplify
ITGA2b: Forward 5’-ATTCCTGTTTAGGACGTTTGGG and Reverse: 5’-TCTTGACTT
GCGTTTAGGGC [24] with the housekeeping gene coding for GAPDH (Forward 5’-T
GACGTGCCGCCTGGAGAAA and Reverse 5’-AGTGTAGCCCAAGATGCCCTTCAG).
Quantitative RT-PCR was run on a Bio-Rad CFX96 thermal cycler, and threshold values (Ct)
of the target gene were normalized to GAPDH (ΔCt = CtITGA2b –CtGAPDH). The relative
expression was calculated for each sample versus the mean of total 5 day LN ΔCt: ΔΔCt =
ΔCtsample– ΔCttotal LN at 5 days; and relative quantification was performed as 2-ΔΔCt.
Immunization
Six-week-old mice were injected in both posterior limbs with 70 μg of chicken ovalbumin,
600 μg aluminium hydroxide (Sigma-Aldrich) and 6x108 heat inactivated B. pertussisml-1. A
boost was administrated 2 weeks later. Inguinal and popliteal LN were sampled 4 days later.
Imiquimod Treatment
Adult mice were anesthetized by intraperitoneal injection of ketamine and xylazine (100 μg/g
body weight and 10 μg/g body weight, respectively). Back skin or ear skin received 12.5 μg/g
(0.1mg/kg body weight) of Toll-like receptor (TLR)-7 agonist imiquimod (Aldara), diluted in
RANKL Activates Lymphatic Integrin-αIIb Expression
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neutral cream (Diprobase) [25]. Back skin hair was trimmed before hair removal with cold wax
(Klorane, France). The animals were sacrificed 12h after.
RANKL and Lymphotoxin β Receptor Blockage
The neutralizing anti-RANKL mAb IK22-5 [22] or the rat IgG2a isotype control (BioXell)
were administrated s.c. into 6-week old C57BL/6 mice every 3 days (50 μg/ mouse in sterile
saline) for two weeks and for 3 consecutive days for the third week. The lymphotoxin β recep-
tor -Ig fusion protein or mIgG1 isotype control (20μg/mouse in sterile saline) were adminis-
trated s.c. into 6-week old mice every 3 days for four weeks.
Statistical Analysis
An unpaired two-tailed Student t-test and ANOVA with the Bonferroni method were used to
determine statistically significant differences. The p values<0.05 were considered statistically
significant. GraphPad Prism version 5 for Windows (GraphPad software) was used for the
analysis.
Results
LN LECs Express ITGA2b
Microarray gene expression analysis of murine LN stromal cells had revealed transcription of
Itga2b by LECs but by no other stromal or hematopoietic cells [26]. To study ITGA2b expres-
sion by LECs, we prepared stromal cells from peripheral LNs following the same procedure as
used in the microarray study. LECs (gp38+CD31+), fibroblastic reticular cells (FRCs,
gp38+CD31-), blood endothelial cells (BECs, gp38-CD31+), and pericyte-containing double-
negative cells (DNCs, gp38-CD31-) were identified in the cell suspension (panel A in S1 Fig).
ITGA2b-specific mAbs (MWReg30 and RAM-2), validated on platelets (panel B in S1 Fig),
recognized a major subset of LECs and a minor subset of BECs (Fig 1A and panel A in S1
Fig). To verify whether the labelling was due to platelets bound to the cells, we exposed them
to an antibody specific for glycoprotein subunit GPIbβ (CD42c) that is exclusively carried by
megakaryocytes and platelets [20] (panel B in S1 Fig). The antibody recognized the minor
fraction of BECs but did not interact with LECs (Fig 1B). To further assure that LECs were
platelet-free, ITGA2b+ LECs were FACS sorted and examined for the adherence of platelets by
electron microscopy, however none were found (panel C in S1 Fig). To confirm ITGA2b
expression, LECs were prepared from mice deficient for ITGA2b [15]. As shown in Fig 1C,
LECs from heterozygous mice expressed reduced levels of the integrin and LECs from mice
with the homozygous deletion fully lacked ITGA2b. We next irradiated WT C57BL/6 mice and
adoptively transferred bone marrow from Itga2b-/- mice. Six weeks later, circulating platelets
were devoid of ITGA2b but LECs still expressed the integrin (Fig 1D and panel A in S2 Fig).
Also the staining for platelets on LN cross-sections did not reveal any presence, whereas plate-
lets were found in the spleen red pulp (panel B in S2 Fig). We tested whether the integrin
could be detected on FACS-sorted LECs grown in culture. The cells were labelled for ITGA2b
and the pan-LEC marker mCLCA1 (recognized by mAb 10.1.1, [27,28]). LECs expressing
ITGA2b could be seen, which was found distributed throughout the cell and occasionally con-
centrated at cell-cell junctions (see arrows) (Fig 1E). Finally, to extend this finding to man,
human embryonic mesenteric LNs were processed in a similar fashion to obtain the four stro-
mal subsets (panel C in S2 Fig). An ITGA2b-reactive mAb that recognized platelets from
healthy donors but not from an ITGA2b-deficient Glanzmann donor (panel D in S2 Fig)
RANKL Activates Lymphatic Integrin-αIIb Expression
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labelled LECs but not the other stromal subsets (Fig 1F). Taken together, these finding demon-
strated that LN LECs, but not other stromal cells, express the ITGA2b integrin.
ITGA2B Is Restricted to LN LEC Subsets
Because only a proportion of LN LECs expressed ITGA2b, we next wished to localize the
ITGA2b+ LECs in the mouse LN. ITGA2b immunofluorescence on cross-sections together
with LEC marker mCLCA1 (10.1.1 mAb) revealed that LECs of the medullary and the cortical
area expressed ITGA2b in a heterogenous manner (Fig 2A). Remarkably, the subcapsular
sinus ceiling LECs were totally devoid of ITGA2, while its floor counterpart uniformly
expressed the integrin. We repeated the immunofluorescence with the lymphatic vessel endo-
thelial hyaluronan receptor (Lyve)-1 and observed again a restricted expression of ITGA2b to a
subset of LECs (panel A in S3 Fig). Colabelling for Prox-1, the most specific LEC marker, con-
firmed LEC-restricted ITGA2b staining (panel B in S3 Fig). At E18.5, the subcapsular sinus of
the embryonic inguinal LNs were not yet formed and was constituted of a single layer of Lyve-
1+ LECs expressing the integrin to different extents (Fig 2B). To verify its exclusion from the
subcapsular sinus ceiling-lining cells, LECs of adult mice that express GFP exclusively in this
Fig 1. LN LECs express ITGA2b. (A) Flow cytometry histograms display ITGA2b expression by peripheral (p)LN stromal subsets, lymphatic endothelial
cells (LEC), blood endothelial cells (BEC), fibroblastic reticular cells (FRC) and the pericyte-containing gp38-CD31- double negative cells (DNC). Peripheral
LNs are inguinal, brachial and axial LNs. The percentage ±SD (n = 13) of cells labelled by the mAb is indicated. (B) Histograms of the four stromal cell types
incubated with a mAb specific for platelet-restricted GPIBβ. The percentage ±SD (n = 8) of cells labelled by the antibody is indicated. (C) Histograms show
ITGA2b expression by LECs of WTmice, but reduced and no expression by LECs isolated frommice heterozygous or homozygous for Itga2b genetic
deletion. The graph depicts the mean ± SD (n = 9) percentage of ITGA2b+ LECs in WT controls and in mice heterozygous or homozygous for the Itga2b
genetic deletion. (D) Histograms of ITGA2b expression by platelets and LECs in control mice and in mice after adoptive transfer of Itga2b-/- bone marrow
(n = 8 for adoptive bone marrow transfer, n = 4 for WTmice). The percentage ±SD of ITGA2b+ cells is indicted. (E) Confocal fluorescence microscopy images
of cell-sorted LECs in culture showing mCLCA1 (mAb 10.1.1) (magenta) and ITGA2b (green) expression. (F) Flow cytometry histograms ±SD (n = 2) display
ITGA2b expression within the four stromal subsets of human embryonic mesenteric LN. ***p<0.001.
doi:10.1371/journal.pone.0151848.g001
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subset [2] were labelled for ITGA2b. Indeed, the ACKR4-GFP+ LECs lacked the integrin (Fig
2C). To verify ITGA2b expression in the floor-lining cells, we sorted LECs based on gp38/
CD31 and MAdCAM-1 expression for qRT-PCR analysis. MAdCAM-1 is uniformly carried
by the floor-lining subcapsular sinus LECs but not the ceiling counterpart (panel A in S4 Fig)
and colabelling showed that all MAdCAM-1+ cells express ITGA2b (panel B in S4 Fig). MRCs
identified by RANKL expression localize close to the LECs but do not carry the integrin (panel
C in S4 Fig). In whole adult LN, Itga2bmRNA was barely detectable, however sorted MAd-
CAM-1+ and MAdCAM-1- cells clearly expressed the message (Fig 2D). Sorted LN BECs were
devoid of the mRNA (data not shown). This supports its restricted expression in LECs, and in
particular the floor-lining MAdCAM-1+ LECs. To determine whether ITGA2b is expressed by
non-LN LECs, skin was processed into a cell suspension and LECs were identified as CD45-F4/
80-gp38+CD31+ cells. However, we saw no ITGA2b expression by FACS or qRT-PCR, neither
in LECs from resting skin, after activation with imiquimod [25] or from RANK-transgenic
mice overexpressing RANKL from hair follicles [14,29] (panel D in S4 Fig and data not
shown). Taken together, the data show that ITGA2b is restricted to subsets of LN LECs.
LEC ITGA2b Is Not Required for Residence in Fibronectin-Rich
Environments
To explore the function of ITGA2b for LECs, we first asked whether ITGA2b could heterodi-
merize with ITGB3 to interact with ligands, such as fibronectin. Indeed, ITGB3 was uniformly
expressed by LECs and BECs, while there was little of the β-chain found on FRCs and DNCs
(Fig 3A). We next assessed whether there was a correlation between ITGA2b expression and
Fig 2. ITGA2b is heterogeneously expressed in the adult and embryonic LN. (A) Confocal microscopy images of an adult inguinal LN probed for ITGA2b
together with LECmarker mCLCA1 (mAb 10.1.1) in the subcapsular, the medullary and the cortical sinus. Scale bars are indicated. (B) Confocal microscopy
images of an embryonic (E18.5) inguinal LN of ITGA2b and LECmarker Lyve-1. Higher magnification of boxed area is shown below. (C) Flow cytometry
counterplot of ITGA2b versus ACKR4 expression by LN LECs of ACKR4-GFP transgenic mice. The percentage ±SD (n = 3) of positive cells is indicated. (D)
Mean ± SEM Itga2bmRNA expression of total LN frommice aged 5 days and 8 weeks, and of MAdCAM-1+ and MAdCAM-1- cell-sorted LECs frommice
aged 8 weeks. Statistical analysis: ***p<0.001, ns = non significant by one way Anova with the Bonferroni method.
doi:10.1371/journal.pone.0151848.g002
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residence in a fibronectin-containing environment. To this end, we stained the LN subcapsular
area that contained the ITGA2b+ floor-lining and the ITGA2b- ceiling-lining LECs for fibro-
nectin. It was apparent that this extracellular matrix component was present in both sites, dem-
onstrating that the absence of ITGA2b does not prevent LECs to take up position in the
fibronectin-containing ceiling (Fig 3B). Further, the positioning of the integrin relative to the
sinus luminal or abluminal side was investigated and no preferential location was found (Fig
3C). To explore whether a functional ITGA2b/ITGB3 complex was indeed formed, LECs and,
as controls unstimulated and thrombin-activated platelets, were incubated with the phycoery-
thrin (PE)-conjugated JON/A mAb, which recognizes only the ITGA2b/ITGB3 complex in its
activated state, as found on platelets [30,31]. While agonist stimulated platelets were labelled
with this mAb, LECs were not recognized (Fig 3D). This suggests that if an ITGA2B/ITGB3
heterodimer is formed on LECs, it is not in a configuration recognized by PE-JON/A and may
present a low affinity for its ligands. We therefore asked whether ITGA2b could be substituted
by ITGAV to pair with ITGB3. LECs, alike all other stromal cells, expressed ITGAV, suggesting
that they could anchor to matrix proteins through ITGAV/ITGB3 (Fig 3E). In platelets (panel
B in S1 Fig) but not in embryonic hematopoietic stem cells or mast cells [24,32], ITGA2b is
required to translocate ITGB3 to the cell surface [15,33], raising the question of whether, in the
absence of ITGA2b, ITGB3 would be available to heterodimerize with ITGAV on the cell sur-
face. To assess this issue, we labelled LECs from mice deficient for ITGA2 and observed that
Fig 3. LEC ITGA2b is not required for residence in fibronectin-rich environments. (A) Flow cytometry histograms show the percentage ±SD (n = 4) of
LECs expressing ITGB3 by the four stromal subsets. (B) Confocal microscopic images of a LN subcapsular area labelled for fibronectin (magenta) and
ITGA2b (green). Nuclear coloration was with DAPI. (C) Confocal high resolution microscopy of the subcapsular area labelled for ITGA2b and mCLCA1 (mAb
10.1.1). (D) Histograms show recognition of the active conformation of the ITGA2b/ITGB3 complex on activated platelets but not on LECs or unstimulated
platelets by the PE-conjugated JON/A mAb. (E) Histograms show ITGAV expression ±SD (n = 3) on the stromal subsets. (F) Flow cytometry counterplots of
LECs probed for expression of ITGA2b and ITGB3 in Itga2b+/+, Itga2b+/- and Itga2b-/-mice (n = 3).
doi:10.1371/journal.pone.0151848.g003
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cell surface expression of the ITGB3 was maintained in Itga2b-/- mice (Fig 3F). Taken together,
ITGA2b is not required for residence of the ceiling LECs in its fibronectin-containing environ-
ment, most probably by the formation of an ITGAV/ITGB3 complex that binds with high
affinity to this matrix protein.
The ITGA2b+ Subset Is Sensitive to Activation by RANKL and
Lymphotoxin
We noted that in comparison to peripheral LNs, the proportion of ITGA2b+ LECs was higher
in mesenteric LNs (Fig 4A). Because mesenteric LNs are stimulated by the intestinal micro-
flora, this evoked the possibility that the heterogenous LN ITGA2b expression reflects differ-
ences in cell activation. To test this hypothesis, we administered heat-inactivated Bordetella
pertussis subcutaneously, and after a secondary immunization, compared ITGA2b expression
in draining and non-draining LNs. The proportion of ITGA2b+ LECs was markedly increased
in response to immunization (Fig 4B), while the other stromal cells remained devoid of the
integrin (Fig 4C). The upregulation was not due to platelet adherence to LECs because there
was no recognition of LECs by the GPIbβ-specific mAb (Fig 4D). We also tested whether the
innate immune stimulus imiquimod (TLR7 ligand) resulted in a similar upregulation. LECs
from auricular LNs draining imiquimod or mock-treated ears were analyzed, however, the pro-
portion of ITGA2b+ LECs did not rise after application of the TLR-7 ligand (panel A in S5
Fig). We have previously observed that RANKL activates LN LECs in a transgenic model of
cutaneous RANKL overproduction [14]. Therefore, we determined in these mice whether
RANKL affected ITGA2b levels and indeed found that ITGA2b expression was positively regu-
lated by this TNF-family member (Fig 4E). We addressed the question of whether integrin
upregulation was due to its externalization to the cell surface. In WT controls, immunolabelling
of permeabilized cells revealed a stronger signal compared with the cell surface, however, the
signal was identical in the LECs isolated from the transgenic mice (panel B in S5 Fig). This
suggests that the increased expression of ITGA2b by RANKL stimulation likely involves its
translocation from the cytoplasm to the cell membrane. We tested whether the upregulation
was accompanied by a rise in transcriptional activity. In comparison with WT controls, there
was no major increase in mRNA synthesis in the LEC subsets isolated from the mutant mice
(panel C in S5 Fig). However, because the proportion of MAdCAM-1+ LECs greatly aug-
mented in the transgenic mice (panel C in S5 Fig), the increase in ITGA2b expression in these
mice is principally the result of an expansion of the MAdCAM-1+ subset that naturally
expresses more ITGA2b. We next determined if neutralizing RANKL in WT mice led to a
downregulation of ITGA2b. Administration of RANKL-blocking mAb caused a significant
decrease in ITG2b expression by LECs in comparison to isotype injected controls (Fig 4F).
Immunofluorescence on sections confirmed the strong decline of ITGA2b in subcapsular and
medullary sinuses (Fig 4G). Because in the LN, RANKL is principally produced by the mar-
ginal reticular cells (MRCs) [13], this raised the possibility that MRC RANKL activates LECs
resulting in ITGA2b expression. To address this question, we generated mice conditionally
deficient for RANKL in MRCs by crossing Ccl19-cremice [16] with Ranklf/f mice [17]. These
mice were devoid of RANKL expression by MRCs (panel D in S5 Fig). Analysis of
RANKLΔCCL19 mice showed that the disappearance of MRC RANKL significantly compro-
mised ITGA2b expression (Fig 4H), supporting a role of RANKL in LEC activation. However,
because there was not a complete loss of ITGA2b other factors could contribute to LEC activa-
tion. Indeed, approximately 15% of LECs were double positive for RANK and ITGA2b, sug-
gesting that a proportion of LECs reacts to other stimulatory factors (panel E in S5 Fig). On
the other hand, cutaneous LECs that do not respond to RANKL do not carry any RANK
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(panel F in S5 Fig). In light of similar activities of RANKL and lymphotoxin αβ (LT) [10,34]
and the expression of the LTβ receptor (R) by LECs [35], we asked whether also LT regulated
ITGA2b expression. Therefore, mice were treated with soluble LTβR-Ig to inhibit LTβR signal-
ing [36]. We found that this treatment likewise reduced ITGA2b (Fig 4I). Taken together,
ITGA2b is a novel marker for subsets of LN LECs that respond to activation by TNF-family
members RANKL and LT.
Fig 4. ITGA2b+ LECs are responsive to RANKL and lymphotoxin activation. (A) Mean ± SD (n = 6) percentage of ITGA2b+ LECs of peripheral (p)LNs
(inguinal, axial and brachial) versus mesenteric (mes) LNs. (B) Mice were immunized with heat-inactivated B. pertussis and LEC ITGA2b expression of
draining and non-draining LNs was compared. The graph shows the mean ± SD (n = 6) percentage of ITGA2b+ LECs, revealing increased ITGA2b
proportions in response to immunization. (C) Flow cytometry histograms display representative ITGA2b expression ±SD (n = 6) by stromal subsets of
inguinal and popliteal LNs draining the immunization site. (D) Histograms show reactivity to anti-GPIBβ labelling of stromal subsets of inguinal and popliteal
LNs draining the immunization site. The percentage ±SD (n = 6) of cells labelled by the antibody is indicated. (E) The increase in the proportion of ITGA2b+
pLN LECs from RANK-Tg mice (overproducing soluble RANKL in the skin) compared with LECs of WT controls is shown as mean ± SD (n = 8). (F) Graph
shows reduction in the percentage of ITGA2b+ LECs upon RANKL neutralization (mean ± SD, n = 5). (G) Confocal microscopy imaging in inguinal LN
subcapsular and medullary sinuses of ITGA2b expression (green) by LECs (10.1.1, magenta) after RANKL-neutralization or after administration of isotype-
control antibody. (H) Mean ± SD (n = 9) percentage of ITGA2b+ LECs frommice with conditional deficiency of RANKL in marginal reticular cells (KO) versus
WT littermate controls. (I) Histograms of ITGA2b expression of LECs frommice treated with LTβR-Ig or IgG1 control. The graph depicts the mean ± SD
(n = 3) percentage of ITGA2b+ LECs. *p<0.5, **p < 0.01, ***p < 0.001.
doi:10.1371/journal.pone.0151848.g004
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Discussion
In this study we show that ITGA2b is expressed by a subset of LN LECs in the subcapsular, cor-
tical and medullary sinus. This subset is also marked by MAdCAM-1. The ITGA2b+ popula-
tion is sensitive to stimulation by the TNFSF members RANKL and LT.
ITGA2b is known to be carried by megakaryocytes and platelets as well as by hematopoietic
stem and progenitor cells in the embryo and the adult [7–9,37]. Here we show for the first time
that LN LECs also carry this integrin. A number of studies had analyzed ITGA2b expression
using different experimental approaches, including a genetic reporter system to mark ITGA2b-
expressing cells by β-galactosidase [7–9]. However, these reports, which investigated whole
embryos, the embryonic aorta-gonad-mesonephros region, spleen, thymus and bone marrow,
did not analyze LNs. Although platelets interact with endothelial cells in the embryo during
separation of blood and lymphatic systems [4], the following observations exclude the possibil-
ity that ITGA2b expression by LEC is the result of platelet contamination: (i) the platelet glyco-
protein subunit Iβ was not detected on LECs, (ii) electron microscopy did not reveal platelets
adhering to the cells, (iii) ITGA2b-deficient platelets lacked surface ITGB3, yet the β-chain was
expressed by LECs of Itga2b-/- mice, (iv) after adoptive transfer of Itga2b-/- bone marrow result-
ing in the repopulation of ITGA2b- platelets, the integrin was still expressed by LECs and (vi)
Itga2bmRNA was amplified from sorted LECs. The related BECs were devoid of the integrin,
irrespective of the site of residence or the presence of stimulatory signals. This is supported by
an early report noting the absence of ITGA2b in the blood endothelial cell line bEnd3 [38].
LN LECs and BECs uniformly expressed ITGB3 and ITGAV, while only a subset of LECs
also carried ITGA2b. Both α-chains pair with ITGB3 and recognize similar matrix proteins,
such as fibronectin, fibrinogen, vonWillebrand factor and vitronectin, which raises the ques-
tion of the necessity of the ITGA2b chain. This is in contrast to platelets that predominantly
express ITGA2b to ensure platelet aggregation. Indeed, although ITGA2b was expressed by
LECs in embryonic LNs, its absence had no discernible impact on LN development. In addi-
tion, those LECs that naturally lack ITGA2b are still capable of taking up residence in the fibro-
nectin-rich subcapsular sinus. Further, the absence of polarization towards the luminal or the
abluminal side does not point to a predominant function in cell-cell interaction or cell-extracel-
lular matrix contact. It is likely that LECs rendered genetically deficient for ITGA2b function
normally, since the migration of tissue-derived dendritic cells to the LN cortex of ITGA2b-defi-
cent mice was unperturbed (data not shown). Although we observed a reduction in the number
of B cells, it cannot be excluded that this defect was the result of a loss of ITGA2b from platelets
(data not shown). Indeed, a minor defect in LN structuring during development was seen in
mice lacking platelet CLEC-2 [39]. Further investigation into the specific role of ITGA2b for
LEC function will await the generation of mice with conditional deletion of ITGA2b in these
cells. Inside-out signaling of platelets results in a conformation change of ITGA2b/ITGB3 to
increase affinity for its ligands. This conformation is detected by the PE-conjugated JON/A
mAb. LECs were not recognized by the antibody indicating either that ITGA2b does not pair
with ITGB3 or that the complex is not in the same configuration as that found on platelets. On
the other hand, to our knowledge, this mAb has only been used successfully on activated plate-
lets and may not be a suitable reagent to probe for the ITAG2b/ITGB3 heterodimer on other
cells. It is also noteworthy that although bone marrow-derived mast cells express ITGA2b and
ITGB3, no binding to fibrinogen was seen, and, paradoxically, cell adhesion to fibronectin
increased in ITGA2b-deficient cells [24]. It should also be noted that the densities of the α and
β chains are at least 10-fold higher on platelets owing to their approximately 10-fold smaller
size with roughly equal mean fluorescence intensities, resulting in greatly increasing the
avidity.
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ITGA2b was carried by the subcapsular floor-lining LECs but absent from its ceiling equiva-
lent. Interestingly, this expression pattern was shared with MAdCAM-1. Hence, MAdCAM-1+
LECs displayed the highest Itga2b transcriptional activity. In addition, there was a heteroge-
nous expression of ITGA2b in the medullary and the cortical sinuses. Skin LECs were devoid
of the integrin on protein and mRNA levels in all conditions tested. Difference in tissue versus
secondary lymphoid organ LECs is supported by other examples, such as Sphingosine-1-phos-
phate [3], found expressed by LN LECs, or ITGA9 [40] that is carried exclusively by vessel
LECs. In view of its uniform expression by the subcapsular floor-lining LECs, their juxtaposi-
tion to the RANKL-expressing MRCs, and the finding that RANKL upregulates MAdCAM-1
expression [14], we reasoned that RANKL may control ITGA2b synthesis. Using overexpres-
sion and neutralization / genetic deletion, we showed that RANKL positively regulates the pro-
portion of ITGA2b+ LECs. The finding that conditional deficiency of RANKL fromMRCs
lowers ITGA2b expression to the same extent as RANKL neutralization concords with the idea
that MRC RANKL is the main LN RANKL source and identifies a cellular target for the stromal
cell-produced RANKL. However, in the absence of definite proof that RANKL activates
ITGA2b transcription we cannot completely rule out the possibility that RANKL stimulates
the expansion of the ITGA2b+ subset. Two elements suggested that RANKL is not the exclusive
ITGA2b regulatory factor: (i) RANKL neutralization or genetic deletion do not eliminate its
expression and (ii) only a proportion of ITGA2b+ LECs express RANK. Lymphotoxin and
RANKL share not only biological functions (requirement for secondary lymphoid organ for-
mation), signaling (canonical and non-canonical NF-κB pathways) but also receptor expres-
sion by LECs, so that it appeared rational to investigate the impact of LTβR blockage. Indeed,
administration of LTβR-Ig also led to reduced ITGA2b expression. It is therefore likely that
both RANKL and LT contribute to the expression of this integrin by LECs and that its upregu-
lation in response to immunization is the consequence of stimulatory factors including
RANKL produced by primed T cells and LT expressed by activated B and T cells. The finding
that imiquimod had no effect on ITGA2b may therefore reflect a failure to stimulate RANKL
and LT synthesis. Further work is necessary to determine whether other stimuli such as TNF-α
or T and B cell-released cytokines also impact on ITGA2b expression by LN LECs. Beyond the
question of its function for LN LECs, the ITGA2b integrin sheds a new light on the heterogene-
ity of LECs and their response to activation signals.
Supporting Information
S1 Fig. (A) Left: Flow cytometry dot plot profiles displaying the gating strategy for stromal cell
identification in CD45/Ter119-depleted LN cell suspensions. Right: Flow cytometry histo-
grams show ITGA2b expression by the four stromal subsets using the RAM-2 mAb. The per-
centage ±SD (n = 6) of cells labelled by the antibody is indicated. (B) Validation of MWReg30
and RAM.2 (anti-ITGA2b antibodies), RAM.1 (anti-GPIbβ antibody) and 2C9.G2 (anti-
ITGB3 antibody) in WT and knock-out animals. Expression of ITGA2b and ITGB3 was seen
on platelets from Itgab2+/+ mice but not on platelets from Itgab2-/- mice. GPIbβ was present on
platelets of both mice. (C) FACS sorting of Itga2b+ LECs. Plots for sorting and post-sort analy-
ses are represented. Sorted cells were then viewed by transmission electron microscopy. Eight
representative images of LECs are shown together with an image of platelets with the same
magnification.
(TIF)
S2 Fig. (A) Microscopy images of a LN of mouse that was lethally irradiated and had received
Itgab2-/- bone marrow, labelled for ITGA2b (clone MWReg30) and the LEC marker mCLCA1
(mAb 10.1.1). (B) Staining of spleen and LN sections for platelets using the platelet-specific
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glycoprotein GPIbβ (mAb RAM.1) together with LEC marker mCLCA1 (mAb 10.1.1).
RP = red pulp. (C) Flow cytometry dot plot profiles displaying the gating strategy for stromal
cell identification from human embryonic mesenteric LN. (D) The histogram displays ITGA2b
expression (SDF.2 mAb) on human healthy donor platelets but not on platelets from a patient
with Glanzmann’s thrombasthenia. Representative image of over 10 donors.
(TIF)
S3 Fig. (A) Confocal microscopy images of an inguinal LN, showing the medullary and the
subcapsular sinus LECs labelled with anti-Lyve-1 and anti-ITGA2b mAbs. Images are repre-
sentative of 2 different experiments. (B) Upper: Images of the medullary region stained for
ITGA2b and nuclear Prox-1. Lower: Images of the subcapsular sinus from a LN of a mouse
expressing GFP under the control of the Prox-1 promoter.
(TIF)
S4 Fig. (A) Confocal microscopy images of a LN subcapsular sinus showing MAdCAM-1
expression by the floor-lining but not the ceiling-lining LECs marked with the 10.1.1 mAb. (B)
Images show overlapping staining of subcapsular sinus LECs for mCLCA1 (mAb 10.1.1),
MAdCAM-1 (MECA-367) and ITGA2b (MWReg30). The flow cytometry profile shows dou-
ble labelling of LECs with ITGA2b and MAdCAM-1. (C) Confocal microscopy images of a LN
subcapsular sinus labelled for MAdCAM-1 and RANKL. (D) Flow cytometry of mouse skin:
upper dot plot panels depict the gating strategy for skin LECs; lower panels show the histo-
grams for ITGA2b expression ± SD (n = 3) of skin LECs from control mice, imiquimod-treated
skin and from RANK-transgenic skin (overexpressing RANKL in the hair follicles).
(TIF)
S5 Fig. (A) Histograms show ITGA2b expression of auricular LN LECs from mice non-treated
or after 2 or 4 day topical application of imiquimod on ears. Graph depicts the levels (geomet-
ric mean of fluorescence) of ITGA2b expression (mean ±SD, n = 3–4). (B) Histograms show
LEC ITGA2b expression on the cell surface or on the cell surface and in the cytoplasm for WT
and RANK-Tg mice. The graphs show the expression levels of the integrin in LECs after cell
surface or intracellular/cell surface labelling. The data for WT mice are of 8 mice and for Tg
mice are of 4 mice. (C) Graphs show mean ± SEM (n = 6) Itga2bmRNA expression of total
LN, MAdCAM-1+ and MAdCAM-1- LECs fromWT and RANK-Tg mice (left) normalized
with respect to WT 5 day LNs. Right: Graph shows the mean ± SD (n = 10) percentage of
MAdCAM-1+ LECs in WT and RANK-Tg mice measured by flow cytometry. (D) Confocal
microscopy images of WT and RANKLΔCcl19 inguinal LNs, showing the subcapsular sinus area
labelled for mCLCA1 (red) and RANKL (green). The RANKLΔCcl19 LN is devoid of RANKL
expression. Representative of 4 mice. (E) Counterplot of LN LECs double stained for ITGA2b
and RANK expression. Graph bar (n = 6) shows the percentage of LECs expressing both
ITGA2b and RANK. (F) Histograms show RANK expression by LECs and BECs from skin and
LNs. The percentage of ITGA2b+ cells is indicated. Graph shows their mean ± SD (n = 6) per-
centages. ns = not significant, p<0.5, p< 0.01, p< 0.001.
(TIF)
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